- Home
- CRDF vs FINW Comparison
CRDF vs FINW Comparison
Compare CRDF & FINW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- FINW
- Stock Information
- Founded
- CRDF 1999
- FINW 1999
- Country
- CRDF United States
- FINW United States
- Employees
- CRDF N/A
- FINW N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- FINW Commercial Banks
- Sector
- CRDF Health Care
- FINW Finance
- Exchange
- CRDF Nasdaq
- FINW Nasdaq
- Market Cap
- CRDF 240.2M
- FINW 212.8M
- IPO Year
- CRDF N/A
- FINW 2021
- Fundamental
- Price
- CRDF $3.45
- FINW $16.41
- Analyst Decision
- CRDF Strong Buy
- FINW Buy
- Analyst Count
- CRDF 3
- FINW 3
- Target Price
- CRDF $10.33
- FINW $18.67
- AVG Volume (30 Days)
- CRDF 1.4M
- FINW 15.2K
- Earning Date
- CRDF 02-27-2025
- FINW 01-30-2025
- Dividend Yield
- CRDF N/A
- FINW N/A
- EPS Growth
- CRDF N/A
- FINW N/A
- EPS
- CRDF N/A
- FINW 1.06
- Revenue
- CRDF $688,000.00
- FINW $69,509,000.00
- Revenue This Year
- CRDF $25.03
- FINW N/A
- Revenue Next Year
- CRDF N/A
- FINW $10.13
- P/E Ratio
- CRDF N/A
- FINW $15.52
- Revenue Growth
- CRDF 49.57
- FINW 4.87
- 52 Week Low
- CRDF $1.44
- FINW $8.72
- 52 Week High
- CRDF $6.42
- FINW $20.50
- Technical
- Relative Strength Index (RSI)
- CRDF 45.05
- FINW 48.28
- Support Level
- CRDF $3.33
- FINW $15.33
- Resistance Level
- CRDF $4.89
- FINW $16.69
- Average True Range (ATR)
- CRDF 0.31
- FINW 0.60
- MACD
- CRDF -0.15
- FINW 0.06
- Stochastic Oscillator
- CRDF 10.56
- FINW 63.72
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank also has established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.